TOP_December 2010_v4_TOP 11/16/10 3:04 PM Page 29
Personal Finance aggressive savings plan. Think about the lifestyle you want during retirement. Do you plan to travel more or indulge in expensive hobbies? Will you continue to work part-time for an employer or on your own? • Calculate the cost of retirement once you determine the lifestyle you want. Consider the additional healthcare costs that often accom-
pany aging and determine the income you will need for these expenses. • Identify your sources of retirement income, including your personal savings and investments, your IRA, 401(k), or other employee-sponsored plans, and Social Security. How much income will these
sources provide? Determine the amount and frequency of withdrawals you will need from these vehicles without depleting them. • Review your portfolio and adjust your savings and investment strategies if you do not think you will have enough to meet your retirement needs.
• Monitor your progress. Once strategies are in place, you will need to follow your progress to make sure you are on track to reach your retirement savings goals. Keep in mind that you will probably need to make adjustments in your planning to reflect market changes and family needs. ●
A Friday Satellite Symposium preceding the 52nd ASH Annual Meeting HEMATOLOGIC CANCERS
Lymphoma Expert Outlines Recent Refinements... Continued from page 26
more favorable prognostic disease that can be ‘watched and waited’ or given single-agent rituximab.” Shift in treatment goals At the same time that progress in treatment efficacy has been occurring, a change with respect to general attitudes about side effects has led to a shift in treatment goals. The operant question, O’Connor said, has become, “Are we treating that patient with curative intent or as someone with a chronic disease? I think we’re getting much more sophisticated and less addicted to the idea that everybody needs to be cured.” Follicular lymphoma, he continued, is a great example, because it is a disease of people who are older than 60 years. With simple, well-tolerated therapies like rituximab, patients can be kept alive for 15 to 20 years or more, and will likely die of something other than the cancer. If the treatment goal is to cure the patient, for example, someone with Hodgkin lymphoma or with DLBCL, then asking them to tolerate a little bit more toxicity and risk for the bigger gain is justified. But with indolent disease, excessive treatment or overuse of chemotherapy will, with time, only make the lymphoma more drug resistant and the natural host cells more sensitive to future therapy. “There, I believe, we are getting a lot wiser and smarter about titrating therapies for the aggressiveness of the disease. We’re really trying to manage the patients as if they have a chronic disease, much the way cardiologists manage heart disease or an endocrinologist manages diabetes. The idea is that we don’t need to cure everybody, and, in many cases, we now have the pharmacologic tools to manage them.” ●
www.TheOncologyPharmacist.com
Challenging Cases in Multiple Myeloma A Dialogue Between Community and Academic Clinicians to Improve Patient Care and Outcomes December 3, 2010 Rosen Centre Hotel Ballrooms A & B, Orlando, Florida Register online today at www.myelomacases.com/register PROGRAM DESCRIPTION
PROGRAM AGENDA
This continuing medical education symposium will serve as a forum for discussion of current questions and concerns regarding the treatment and management of patients through the multiple myeloma (MM) life cycle. A panel of domestic and international myeloma experts will be joined by representatives from community cancer care facilities and private oncology practices. By thoroughly engaging participants with interactive cases and physician point-counterpoint-style discussions, this symposium will provide evidence-based treatment and management recommendations and address new treatment regimens and management strategies based on recent clinical trials and emerging data. In addition to considering differences in domestic and international care, barriers and/or limitations faced by community cancer centers and private-practice oncologists will be debated.
12:30 -
1:00 PM
Registration and Lunch Service
1:00 -
1:10 PM
Welcome and Introduction Sundar Jagannath, MD - Chair
CASE PRESENTATIONS Each case will be presented by an expert faculty member and discussed by the international and community panel. 1:10 – 1:40 PM
Case 1: Difficult diagnosis G. David Roodman, MD, PhD
1:40 – 2:10 PM
Case 2: Newly diagnosed, stem cell transplant eligible patient Sundar Jagannath, MD
2:10 – 2:40 PM
Case 3: First-line therapy in a non-SCT eligible patient Stefan Knop, MD
2:40 – 3:10 PM
Case 4: Multiple risk factors Jonathan L. Kaufman, MD
3:10 – 3:40 PM
Case 5: Treatment of MM across the life cycle Noopur Raje, MD
3:40 -
3:50 PM
Question & Answer Session
3:50 -
4:00 PM
Closing Remarks Sundar Jagannath, MD
LEARNING OBJECTIVES At the end of this activity participants will be able to: • Apply early management strategies that consider new diagnostic and staging criteria for SMM, MGUS, and MM and new imaging studies in order to improve prognosis for your patients. • Evaluate novel therapeutic regimens as induction therapy for your patients considering an SCT in order to provide the most rapid response and allow the largest amount of stem cell collection, while maintaining safety and tolerance. • Integrate novel agent-based regimens that provide optimal outcomes and a survival benefit into your management strategy for patients ineligible for SCT after appraising emerging data from clinical trials. • Identify patient- and disease-associated factors that impact choice of therapeutic agent and formulate management strategies using a risk-adapted approach to treatment of MM. • Construct optimal treatment regimens based on novel combinations and make informed treatment decisions in order to improve the long-term outlook for myeloma patients across the life cycle of the disease.
TARGET AUDIENCE This activity has been developed for hematologists and medical oncologists, as well as nurses, pharmacists, and other allied health professionals who are interested in meeting the challenges faced when treating patients with multiple myeloma in academic and community settings.
ACCREDITATION INFORMATION Physician Accreditation The University of Cincinnati designates this activity for a maximum of 3 AMA PRA Category 1 Credits ™. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians should only claim credit commensurate with the extent of their participation in the activity. Registered Nurse Designation Medical Learning Institute, Inc. (MLI) Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 3.0 contact hours. Registered Pharmacy Designation Medical Learning Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 3.0 contact hours (0.3 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-10-058-L01-P.
FACULTY CHAIR: Sundar Jagannath, MD Professor, Hematology and Medical Oncology Mount Sinai School of Medicine’s Tisch Cancer Institute Director of the Multiple Myeloma Program, The Mount Sinai Medical Center New York, NY Leon Dragon, MD, FACP Medical Director Kellogg Cancer Center Northshore University HealthSystem Highland Park, IL
Stefan Knop, MD University Hospital Würzburg Würzburg, Germany
Charles M. Farber, MD, PhD Section Chief of Hematology and Oncology Department of Medicine Carol G. Simon Cancer Center, Morristown, NJ Shoba Kankipati, MD Associate Physician EPIC Care East Bay Partners in Cancer Care San Francisco Bay Area, CA Jonathan L. Kaufman, MD Assistant Professor Blood and Marrow Transplantation Department of Hematology and Medical Oncology Emory University School of Medicine Member, Winship Cancer Institute Emory University, Atlanta, GA
Noopur Raje, MD Associate Professor of Medicine Harvard Medical School Director, Center for Multiple Myeloma Massachusetts General Hospital Boston, MA G. David Roodman, MD, PhD Professor of Medicine Vice Chair for Research Department of Medicine Director, Myeloma Program Director, Bone Biology Center University of Pittsburgh Medical Center Pittsburgh, PA Ari Umutyan, MD Redwood Regional Medical Group Hematology and Medical Oncology Napa, CA
ACKNOWLEDGMENT This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc.
This activity is jointly sponsored by the University of Cincinnati, Medical Learning Institute, Inc., a nonprofit medical accreditation company, and Center of Excellence Media, LLC.
December 2010 I VOL 3, NO 8
29